|
Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology
|
25 June 2018 |
|
New long-term data confirm Roche’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
|
15 June 2018 |
|
FDA grants Priority Review to Roche’s Hemlibra for people with haemophilia A without factor VIII inhibitors
|
07 June 2018 |
|
FDA grants priority review to Roche's cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer
|
08 May 2018 |
|
Roche reports a strong start in 2018
|
30 April 2018 |
|
New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis
|
24 April 2018 |
|
FDA grants Breakthrough Therapy Designation for Roche's Hemlibra in haemophilia A without inhibitors
|
17 April 2018 |
|
Roche to acquire Flatiron Health to accelerate industry-wide development and delivery of breakthrough medicines for patients with cancer
|
21 February 2018 |
|
Roche purchases shares in tender offer for Ignyta, Inc.
|
08 February 2018 |
|
Roche reports good results in 2017
|
01 February 2018 |
|
Roche and Ignyta reach definitive merger agreement
|
22 December 2017 |
|
Roche to acquire Viewics, Inc. to provide data-driven lab business analytics and add further digital capabilities along the laboratory value chain
|
20 November 2017 |
|
Roche reports strong sales growth in the first nine months of 2017
|
24 October 2017 |
|
Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams
|
09 October 2017 |
|
Roche reports strong performance in the first half of 2017
|
01 August 2017 |
|
Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine
|
10 July 2017 |
|
Roche acquires mySugr to form a leading open platform for digital diabetes management
|
03 July 2017 |
|
FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
|
23 June 2017 |
|
Roche's employee-driven philanthropic campaign sets new record
|
14 June 2017 |
|
Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer
|
09 June 2017 |